Arbutus Biopharma Cp (ABUS)

$3.06 -0.08 (-2.55%)
Market Cap 592.57M
Revenue (ttm) 18.14M
Net Income (ttm) -72.85M
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume 649,900
Avg Vol 936,122
Day's Range N/A - N/A
Shares Out 188.72M
Stochastic %K 2%
Beta 1.98
Analysts Strong Sell
Price Target $4.50

Company Profile

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reaw...

Industry: Biotechnology
Sector: Healthcare
Phone: 267 469 0914
Address:
701 Veterans Circle, Warminster, United States
hopeful2bright
hopeful2bright Jun. 4 at 7:45 PM
$ABUS Moderna + PFE + HepB + Genevant ownership = $$$ Better than a CD! Like getting a payout on a death certificate when ABUS goes nighty nighty. Institutions in, I'm in for little less than mill. Diversify everyone, this is my diversification. I'll hold for payout and see anyone that wants to join me in Tahiti.
3 · Reply
mj6534
mj6534 Jun. 4 at 7:36 PM
$ABUS sick of this tbh. Can’t leave, won’t leave. I’m up 40% on 8k shares but I hate staying
0 · Reply
DocPharm
DocPharm Jun. 4 at 7:35 PM
$ABUS they deserved the compensation. That’s how I told my friends and family to vote too. They crushed it. Did exactly what we needed. Only downside is the tight lips, but Loose lips sink buses - or something like that
2 · Reply
LM_Johanssen
LM_Johanssen Jun. 4 at 7:01 PM
$ABUS The hotel california of stocks
1 · Reply
Nile1
Nile1 Jun. 4 at 3:34 PM
$ABUS
1 · Reply
pooldude44646
pooldude44646 Jun. 4 at 12:28 PM
$ABUS Is Arbutus evaluating a return of capital to shareholders in Q3 2026?
3 · Reply
StockosaurusTex
StockosaurusTex Jun. 4 at 10:48 AM
$ABUS
0 · Reply
Blueviking
Blueviking Jun. 4 at 8:22 AM
$ABUS They can play all they want Never getting my shares!
1 · Reply
jaspershe
jaspershe Jun. 4 at 12:22 AM
$ABUS team of mofo’s https://www.mofo.com/resources/news/260303-arbutus-settlement-moderna
0 · Reply
jaspershe
jaspershe Jun. 4 at 12:19 AM
$ABUS any news on the covid vaccine that they announced were developing some 3-4 years ago?
1 · Reply
Latest News on ABUS
Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 13, 2026, 7:30 AM EDT - 22 days ago

Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update

Arbutus Biopharma Quarterly report: Q1 2026

May 13, 2026, 7:00 AM EDT - 22 days ago

Arbutus Biopharma Quarterly report: Q1 2026

Arbutus Biopharma Earnings release: Q1 2026

May 13, 2026, 7:00 AM EDT - 22 days ago

Arbutus Biopharma Earnings release: Q1 2026

Arbutus Biopharma granted Fast Track designation for imdusiran

2026-04-15T11:35:22.000Z - 7 weeks ago

Arbutus Biopharma granted Fast Track designation for imdusiran

Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B

Apr 15, 2026, 7:30 AM EDT - 7 weeks ago

Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B

Arbutus Biopharma Proxy statement: Proxy filing

Apr 14, 2026, 8:00 AM EDT - 7 weeks ago

Arbutus Biopharma Proxy statement: Proxy filing

Arbutus Biopharma Proxy statement: Proxy filing

Apr 14, 2026, 8:00 AM EDT - 7 weeks ago

Arbutus Biopharma Proxy statement: Proxy filing

Arbutus Biopharma price target lowered to $5.50 from $7 at Jefferies

2026-04-07T14:33:40.000Z - 2 months ago

Arbutus Biopharma price target lowered to $5.50 from $7 at Jefferies

MRNA

Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update

Mar 23, 2026, 7:30 AM EDT - 2 months ago

Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update

Arbutus Biopharma Earnings release: Q4 2025

Mar 23, 2026, 7:00 AM EDT - 2 months ago

Arbutus Biopharma Earnings release: Q4 2025

Arbutus Biopharma Annual report: Q4 2025

Mar 23, 2026, 7:00 AM EDT - 2 months ago

Arbutus Biopharma Annual report: Q4 2025

Why Is Moderna (MRNA) Stock Surging Today, 3/4/26?

2026-03-04T16:55:47.000Z - 3 months ago

Why Is Moderna (MRNA) Stock Surging Today, 3/4/26?

MRNA

Moderna resolves litigation with Arbutus, to pay up to $2.25B in settlement

2026-03-04T11:49:13.000Z - 3 months ago

Moderna resolves litigation with Arbutus, to pay up to $2.25B in settlement

MRNA ROIV

Moderna to Pay $950 Million to Settle Patent Cases From Arbutus, Genevant

Mar 3, 2026, 4:46 PM EST - 3 months ago

Moderna to Pay $950 Million to Settle Patent Cases From Arbutus, Genevant

MRNA

Moderna agrees to pay up to $2.25 billion to settle COVID vaccine patent dispute

Mar 3, 2026, 4:26 PM EST - 3 months ago

Moderna agrees to pay up to $2.25 billion to settle COVID vaccine patent dispute

MRNA ROIV

Genevant, Arbutus announce $2.25B global settlement with Moderna

2026-03-03T21:24:20.000Z - 3 months ago

Genevant, Arbutus announce $2.25B global settlement with Moderna

MRNA ROIV

Roivant Announces Genevant Sciences' and Arbutus Biopharma's $2.25 Billion Global Settlement With Moderna

Mar 3, 2026, 4:15 PM EST - 3 months ago

Roivant Announces Genevant Sciences' and Arbutus Biopharma's $2.25 Billion Global Settlement With Moderna

ROIV MRNA

Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna

Mar 3, 2026, 4:15 PM EST - 3 months ago

Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna

ROIV MRNA

Moderna Resolves Global Patent Litigation with Arbutus/Genevant

Mar 3, 2026, 4:15 PM EST - 3 months ago

Moderna Resolves Global Patent Litigation with Arbutus/Genevant

MRNA

Arbutus faces higher bar to argue infringement by Moderna, says Jefferies

2026-02-02T19:50:34.000Z - 4 months ago

Arbutus faces higher bar to argue infringement by Moderna, says Jefferies

MRNA

Moderna reverses lower after court issues memo in patent fight with Arbutus

2026-02-02T19:35:56.000Z - 4 months ago

Moderna reverses lower after court issues memo in patent fight with Arbutus

MRNA

Moderna rises after Delaware court issues memo in patent fight with Arbutus

2026-02-02T18:55:19.000Z - 4 months ago

Moderna rises after Delaware court issues memo in patent fight with Arbutus

MRNA

European Patent Office ruling ‘clear win’ for Moderna, says Citi

2026-01-19T17:30:39.000Z - 4 months ago

European Patent Office ruling ‘clear win’ for Moderna, says Citi

MRNA

Arbutus says European patent revoked by European Patent Office

2026-01-19T16:35:08.000Z - 4 months ago

Arbutus says European patent revoked by European Patent Office

MRNA

Arbutus Biopharma loses patent appeal in Europe, Bloomberg reports

2026-01-16T15:40:26.000Z - 4 months ago

Arbutus Biopharma loses patent appeal in Europe, Bloomberg reports

MRK MRNA

Arbutus Biopharma reports Q3 EPS (4c), consensus (5c)

2025-11-13T12:41:19.000Z - 7 months ago

Arbutus Biopharma reports Q3 EPS (4c), consensus (5c)

Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 13, 2025, 7:30 AM EST - 7 months ago

Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Arbutus Biopharma Earnings release: Q3 2025

Nov 13, 2025, 7:00 AM EST - 7 months ago

Arbutus Biopharma Earnings release: Q3 2025

Arbutus Biopharma Quarterly report: Q3 2025

Nov 13, 2025, 7:00 AM EST - 7 months ago

Arbutus Biopharma Quarterly report: Q3 2025

Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025

Oct 7, 2025, 8:00 AM EDT - 8 months ago

Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025

Arbutus Biopharma Earnings release: Q2 2025

Aug 6, 2025, 4:00 PM EDT - 10 months ago

Arbutus Biopharma Earnings release: Q2 2025

Arbutus Biopharma Quarterly report: Q2 2025

Aug 6, 2025, 4:00 PM EDT - 10 months ago

Arbutus Biopharma Quarterly report: Q2 2025

Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 6, 2025, 7:30 AM EDT - 10 months ago

Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus

Jun 25, 2025, 7:30 AM EDT - 1 year ago

Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus

Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 14, 2025, 7:30 AM EDT - 1 year ago

Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update

Arbutus Biopharma Quarterly report: Q1 2025

May 14, 2025, 7:30 AM EDT - 1 year ago

Arbutus Biopharma Quarterly report: Q1 2025

Arbutus Biopharma Earnings release: Q1 2025

May 14, 2025, 7:30 AM EDT - 1 year ago

Arbutus Biopharma Earnings release: Q1 2025

Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025

May 7, 2025, 2:01 AM EDT - 1 year ago

Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025

Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025

Apr 23, 2025, 2:01 AM EDT - 1 year ago

Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025

Arbutus Biopharma Proxy statement: Proxy Filing

Apr 4, 2025, 8:00 AM EDT - 1 year ago

Arbutus Biopharma Proxy statement: Proxy Filing

Arbutus Biopharma Proxy statement: Proxy Filing

Apr 4, 2025, 8:00 AM EDT - 1 year ago

Arbutus Biopharma Proxy statement: Proxy Filing

Arbutus Biopharma Cuts Workforce by More Than Half, Hires New CFO in Exec Shuffle

Mar 27, 2025, 7:56 AM EDT - 1 year ago

Arbutus Biopharma Cuts Workforce by More Than Half, Hires New CFO in Exec Shuffle

Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update

Mar 27, 2025, 7:30 AM EDT - 1 year ago

Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update

Arbutus Biopharma Earnings release: Q4 2024

Mar 27, 2025, 7:30 AM EDT - 1 year ago

Arbutus Biopharma Earnings release: Q4 2024

Arbutus Biopharma Annual report: Q4 2024

Mar 27, 2025, 7:30 AM EDT - 1 year ago

Arbutus Biopharma Annual report: Q4 2024

Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna

Mar 3, 2025, 9:15 AM EST - 1 year ago

Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna

ROIV

Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO

Feb 25, 2025, 7:00 AM EST - 1 year ago

Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO

Arbutus Provides 2025 Corporate and Financial Update

Jan 13, 2025, 7:30 AM EST - 1 year ago

Arbutus Provides 2025 Corporate and Financial Update

Arbutus Biopharma Transcript: Status Update

Dec 3, 2024, 11:00 AM EST - 1 year ago

Arbutus Biopharma Transcript: Status Update

Whitefort Capital Sends Letter to Arbutus Biopharma Board of Directors

Dec 3, 2024, 8:00 AM EST - 1 year ago

Whitefort Capital Sends Letter to Arbutus Biopharma Board of Directors

Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat

Nov 26, 2024, 7:30 AM EST - 1 year ago

Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat

Arbutus Biopharma Transcript: Jefferies London Healthcare Conference 2024

Nov 21, 2024, 7:00 AM EST - 1 year ago

Arbutus Biopharma Transcript: Jefferies London Healthcare Conference 2024

Arbutus' Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon

Nov 15, 2024, 11:02 AM EST - 1 year ago

Arbutus' Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon

Arbutus to Present at Jefferies London Healthcare Conference

Nov 14, 2024, 7:30 AM EST - 1 year ago

Arbutus to Present at Jefferies London Healthcare Conference

Arbutus Biopharma Earnings Call Transcript: Q3 2024

Nov 6, 2024, 8:45 AM EST - 1 year ago

Arbutus Biopharma Earnings Call Transcript: Q3 2024

Arbutus Biopharma Quarterly report: Q3 2024

Nov 6, 2024, 8:45 AM EST - 1 year ago

Arbutus Biopharma Quarterly report: Q3 2024

Arbutus Biopharma Earnings release: Q3 2024

Nov 6, 2024, 8:45 AM EST - 1 year ago

Arbutus Biopharma Earnings release: Q3 2024

Arbutus Biopharma Registration statement: Registration Filing

Nov 6, 2024, 7:00 AM EST - 1 year ago

Arbutus Biopharma Registration statement: Registration Filing

Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update

Oct 23, 2024, 7:30 AM EDT - 1 year ago

Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update

Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting® 2024

Oct 15, 2024, 8:16 AM EDT - 1 year ago

Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting® 2024

Arbutus Biopharma Transcript: H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference

Oct 8, 2024, 1:30 PM EDT - 1 year ago

Arbutus Biopharma Transcript: H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference

Arbutus Biopharma Transcript: Baird's 2024 Global Healthcare Conference

Sep 10, 2024, 8:30 AM EDT - 1 year ago

Arbutus Biopharma Transcript: Baird's 2024 Global Healthcare Conference

Arbutus Biopharma Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 9, 2024, 8:00 AM EDT - 1 year ago

Arbutus Biopharma Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Arbutus to Participate in Two Upcoming Investor Conferences

Sep 3, 2024, 7:30 AM EDT - 1 year ago

Arbutus to Participate in Two Upcoming Investor Conferences

Arbutus Biopharma Earnings Call Transcript: Q2 2024

Aug 1, 2024, 8:45 AM EDT - 2 years ago

Arbutus Biopharma Earnings Call Transcript: Q2 2024

Arbutus Biopharma Quarterly report: Q2 2024

Aug 1, 2024, 8:45 AM EDT - 2 years ago

Arbutus Biopharma Quarterly report: Q2 2024

Arbutus Biopharma Earnings release: Q2 2024

Aug 1, 2024, 8:45 AM EDT - 2 years ago

Arbutus Biopharma Earnings release: Q2 2024

Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 1, 2024, 7:30 AM EDT - 2 years ago

Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Arbutus to Report Second Quarter 2024 Financial Results and Provide Corporate Update

Jul 18, 2024, 7:30 AM EDT - 2 years ago

Arbutus to Report Second Quarter 2024 Financial Results and Provide Corporate Update

Treatment with Arbutus' Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels

Jun 6, 2024, 11:15 AM EDT - 2 years ago

Treatment with Arbutus' Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels

Arbutus Biopharma Transcript: Jefferies 2024 Global Healthcare Conference

Jun 5, 2024, 9:30 AM EDT - 2 years ago

Arbutus Biopharma Transcript: Jefferies 2024 Global Healthcare Conference

Arbutus' Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure

Jun 5, 2024, 2:30 AM EDT - 2 years ago

Arbutus' Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure

Arbutus Distributors Ltd. News Release

Jun 3, 2024, 9:50 AM EDT - 2 years ago

Arbutus Distributors Ltd. News Release

Arbutus to Participate in Jefferies Global Healthcare Conference

May 29, 2024, 7:30 AM EDT - 2 years ago

Arbutus to Participate in Jefferies Global Healthcare Conference

Arbutus to Present Imdusiran Data at EASL Congress 2024

May 22, 2024, 2:00 AM EDT - 2 years ago

Arbutus to Present Imdusiran Data at EASL Congress 2024

Arbutus Biopharma Transcript: H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

May 20, 2024, 3:30 PM EDT - 2 years ago

Arbutus Biopharma Transcript: H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

Whitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders Outlining Paths to Maximize Value

May 17, 2024, 9:00 AM EDT - 2 years ago

Whitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders Outlining Paths to Maximize Value

Arbutus Biopharma Transcript: The Citizens JMP Life Sciences Conference

May 14, 2024, 9:30 AM EDT - 2 years ago

Arbutus Biopharma Transcript: The Citizens JMP Life Sciences Conference

Arbutus Biopharma Earnings Call Transcript: Q1 2024

May 2, 2024, 8:45 AM EDT - 2 years ago

Arbutus Biopharma Earnings Call Transcript: Q1 2024

Arbutus Biopharma Quarterly report: Q1 2024

May 2, 2024, 8:45 AM EDT - 2 years ago

Arbutus Biopharma Quarterly report: Q1 2024

Arbutus Biopharma Earnings release: Q1 2024

May 2, 2024, 8:45 AM EDT - 2 years ago

Arbutus Biopharma Earnings release: Q1 2024

Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 2, 2024, 7:30 AM EDT - 2 years ago

Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update

Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024

May 2, 2024, 7:25 AM EDT - 2 years ago

Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024

Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update

Apr 18, 2024, 7:30 AM EDT - 2 years ago

Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update

Arbutus Biopharma Proxy statement: Proxy Filing

Apr 10, 2024, 8:00 AM EDT - 2 years ago

Arbutus Biopharma Proxy statement: Proxy Filing

Arbutus Biopharma Proxy statement: Proxy Filing

Apr 10, 2024, 8:00 AM EDT - 2 years ago

Arbutus Biopharma Proxy statement: Proxy Filing

Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna

Apr 4, 2024, 8:30 AM EDT - 2 years ago

Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna

Arbutus Biopharma Transcript: Barclays 26th Annual Global Healthcare Conference 2024

Mar 12, 2024, 2:05 PM EDT - 2 years ago

Arbutus Biopharma Transcript: Barclays 26th Annual Global Healthcare Conference 2024

Arbutus Biopharma Earnings Call Transcript: Q4 2023

Feb 29, 2024, 8:45 AM EST - 2 years ago

Arbutus Biopharma Earnings Call Transcript: Q4 2023

Arbutus Biopharma Annual report: Q4 2023

Feb 29, 2024, 8:45 AM EST - 2 years ago

Arbutus Biopharma Annual report: Q4 2023

Arbutus Biopharma Earnings release: Q4 2023

Feb 29, 2024, 8:45 AM EST - 2 years ago

Arbutus Biopharma Earnings release: Q4 2023

Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update

Feb 29, 2024, 7:30 AM EST - 2 years ago

Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update

Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update

Feb 15, 2024, 7:30 AM EST - 2 years ago

Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update

Arbutus Announces 2024 Corporate Objectives and Provides Financial Update

Jan 8, 2024, 7:30 AM EST - 2 years ago

Arbutus Announces 2024 Corporate Objectives and Provides Financial Update

Arbutus Biopharma Transcript: 14th Annual Jefferies London Healthcare Conference 2023

Nov 15, 2023, 6:30 AM EST - 2 years ago

Arbutus Biopharma Transcript: 14th Annual Jefferies London Healthcare Conference 2023

Arbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver Meeting®

Nov 9, 2023, 4:01 PM EST - 2 years ago

Arbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver Meeting®

Arbutus Biopharma Slides: Corporate Presentation

Nov 9, 2023, 7:00 AM EST - 2 years ago

Arbutus Biopharma Slides: Corporate Presentation

Arbutus Biopharma Earnings Call Transcript: Q3 2023

Nov 7, 2023, 8:45 AM EST - 2 years ago

Arbutus Biopharma Earnings Call Transcript: Q3 2023

Arbutus Biopharma Quarterly report: Q3 2023

Nov 7, 2023, 8:45 AM EST - 2 years ago

Arbutus Biopharma Quarterly report: Q3 2023

Arbutus Biopharma Earnings release: Q3 2023

Nov 7, 2023, 8:45 AM EST - 2 years ago

Arbutus Biopharma Earnings release: Q3 2023

Arbutus Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 7, 2023, 7:30 AM EST - 2 years ago

Arbutus Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Arbutus Announces CEO, William Collier, to Retire December 31, 2023

Nov 7, 2023, 7:15 AM EST - 2 years ago

Arbutus Announces CEO, William Collier, to Retire December 31, 2023

Arbutus to Report Third Quarter 2023 Financial Results and Provide Corporate Update

Oct 24, 2023, 7:30 AM EDT - 2 years ago

Arbutus to Report Third Quarter 2023 Financial Results and Provide Corporate Update

Arbutus to Present at H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Virtual Conference

Oct 18, 2023, 7:30 AM EDT - 2 years ago

Arbutus to Present at H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Virtual Conference

Arbutus Announces Multiple Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2023

Oct 11, 2023, 8:05 AM EDT - 2 years ago

Arbutus Announces Multiple Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2023

Arbutus Biopharma Transcript: Baird's Global Healthcare Conference 2023

Sep 13, 2023, 7:55 AM EDT - 2 years ago

Arbutus Biopharma Transcript: Baird's Global Healthcare Conference 2023

Arbutus Announces Pipeline Updates and Dosing of the First Subject in the Phase 1a/1b Clinical Trial with AB-101; Cash Runway Extended

Sep 11, 2023, 4:15 PM EDT - 2 years ago

Arbutus Announces Pipeline Updates and Dosing of the First Subject in the Phase 1a/1b Clinical Trial with AB-101; Cash Runway Extended

Arbutus Biopharma Earnings Call Transcript: Q2 2023

Aug 3, 2023, 8:45 AM EDT - 3 years ago

Arbutus Biopharma Earnings Call Transcript: Q2 2023

Arbutus Biopharma Quarterly report: Q2 2023

Aug 3, 2023, 8:45 AM EDT - 3 years ago

Arbutus Biopharma Quarterly report: Q2 2023

Arbutus Biopharma Earnings release: Q2 2023

Aug 3, 2023, 8:45 AM EDT - 3 years ago

Arbutus Biopharma Earnings release: Q2 2023

Arbutus Reports Second Quarter 2023 Financial Results and Corporate Update

Aug 3, 2023, 7:30 AM EDT - 3 years ago

Arbutus Reports Second Quarter 2023 Financial Results and Corporate Update

hopeful2bright
hopeful2bright Jun. 4 at 7:45 PM
$ABUS Moderna + PFE + HepB + Genevant ownership = $$$ Better than a CD! Like getting a payout on a death certificate when ABUS goes nighty nighty. Institutions in, I'm in for little less than mill. Diversify everyone, this is my diversification. I'll hold for payout and see anyone that wants to join me in Tahiti.
3 · Reply
mj6534
mj6534 Jun. 4 at 7:36 PM
$ABUS sick of this tbh. Can’t leave, won’t leave. I’m up 40% on 8k shares but I hate staying
0 · Reply
DocPharm
DocPharm Jun. 4 at 7:35 PM
$ABUS they deserved the compensation. That’s how I told my friends and family to vote too. They crushed it. Did exactly what we needed. Only downside is the tight lips, but Loose lips sink buses - or something like that
2 · Reply
LM_Johanssen
LM_Johanssen Jun. 4 at 7:01 PM
$ABUS The hotel california of stocks
1 · Reply
Nile1
Nile1 Jun. 4 at 3:34 PM
$ABUS
1 · Reply
pooldude44646
pooldude44646 Jun. 4 at 12:28 PM
$ABUS Is Arbutus evaluating a return of capital to shareholders in Q3 2026?
3 · Reply
StockosaurusTex
StockosaurusTex Jun. 4 at 10:48 AM
$ABUS
0 · Reply
Blueviking
Blueviking Jun. 4 at 8:22 AM
$ABUS They can play all they want Never getting my shares!
1 · Reply
jaspershe
jaspershe Jun. 4 at 12:22 AM
$ABUS team of mofo’s https://www.mofo.com/resources/news/260303-arbutus-settlement-moderna
0 · Reply
jaspershe
jaspershe Jun. 4 at 12:19 AM
$ABUS any news on the covid vaccine that they announced were developing some 3-4 years ago?
1 · Reply
DocPharm
DocPharm Jun. 3 at 8:23 PM
$ABUS always there for the dips, eventually there won’t be anymore But until then … I patiently wait …& limit add
1 · Reply
LM_Johanssen
LM_Johanssen Jun. 3 at 6:46 PM
$ABUS
0 · Reply
CapitalismUSA
CapitalismUSA Jun. 3 at 4:29 PM
$ABUS Added to my A-BUS load. Thanks for the discount MM crooks.
0 · Reply
Buqqets
Buqqets Jun. 3 at 2:54 PM
$ABUS the volume vs. price movement ratio on this stock has gone from being questionable to downright nonsensical in the last 6 months........when it all shakes out: at least they made the pattern kindergarten-level predictable.
1 · Reply
renoH4
renoH4 Jun. 3 at 2:11 PM
$ABUS ..once upon a time i collected stamps - now i am collecting Arbutus - added again at this supra low level.
0 · Reply
StockosaurusTex
StockosaurusTex Jun. 3 at 12:23 PM
$ABUS
0 · Reply
CapitalismUSA
CapitalismUSA Jun. 3 at 12:08 PM
$ABUS Wake up Androwski, time to complain again today about your stock options.
0 · Reply
Joe_Mama
Joe_Mama Jun. 3 at 1:07 AM
$ABUS Narrowing effect. Going out on a limb here but eventually something might happen. I know that was deep hu?
2 · Reply
jim64
jim64 Jun. 2 at 10:31 PM
$ABUS Roller Coaster! Still betting on this ride!
0 · Reply
SKCSS
SKCSS Jun. 2 at 7:46 PM
$ABUS I know we always go up and down, but couldn't help but notice this time it started to fall when they announced the annual meeting results, which included re-election of the board and approved incentive plan, further diluting our shares.
1 · Reply
Nile1
Nile1 Jun. 2 at 7:37 PM
$ABUS over one million shares, this a serious selling IMO
1 · Reply
Heavey
Heavey Jun. 2 at 7:36 PM
$ABUS if management knew the drugs were failing, would they have sat for re-election?
2 · Reply